
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is particularly modest. We plan to catch up on our reading and napping, hang with a short person or two, and perhaps putter around the castle. And what about you? Now that spring is here, this may be an opportunity to plan a needed break. You could make time for someone special. Adventurous Anglophiles can amuse themselves betting on the Brexit outcome. Or you could simply plan the rest of your life. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …
Nearly 8,000 packets of a Vertex Pharmaceuticals (VRTX) cystic fibrosis drug were destroyed last year while the company and the National Health Service in England haggled over price, The Independent reports. Documents released by the House of Commons Health Committee show that 7,880 packets, each offering a 28-day supply of the drug and intended for distribution around Europe, exceeded their expiry date in 2018. This would be enough to provide the drug for around three months to every one of the 2,834 eligible patients in England.
Sackler family members who control Purdue Pharma allegedly used a web of corporate entities to fraudulently transfer funds from the company to themselves because the company was already insolvent or close to it, The Wall Street Journal writes. An amended lawsuit filed by the New York attorney general is pushing a novel argument that profits paid to Purdue owners should be clawed back because of mounting litigation filed against the company. The claims hinge on a legal theory meant to protect creditors from debtors who try to stash or shield assets for their personal benefit.
It would seem Commissioner G has interests that will, again, possibly continue long past his imminent departure. (Until, of course, they get tweeted down … not that he has seen much of that.) May I observe that we shall miss him, whether for good or ill? “Leich l’shalom,” Scott Gottlieb, MD….